159 related articles for article (PubMed ID: 32055679)
1. oHSV2 Can Target Murine Colon Carcinoma by Altering the Immune Status of the Tumor Microenvironment and Inducing Antitumor Immunity.
Zhang W; Hu X; Liang J; Zhu Y; Zeng B; Feng L; Zhao C; Liu S; Liu B; Zhang K
Mol Ther Oncolytics; 2020 Mar; 16():158-171. PubMed ID: 32055679
[TBL] [Abstract][Full Text] [Related]
2. Oncolytic Herpes Simplex Virus Type 2 Can Effectively Inhibit Colorectal Cancer Liver Metastasis by Modulating the Immune Status in the Tumor Microenvironment and Inducing Specific Antitumor Immunity.
Zhang W; Zeng B; Hu X; Zou L; Liang J; Song Y; Liu B; Liu S
Hum Gene Ther; 2021 Feb; 32(3-4):203-215. PubMed ID: 33176492
[TBL] [Abstract][Full Text] [Related]
3. Antitumor effects of oncolytic herpes simplex virus type 2 against colorectal cancer in vitro and in vivo.
Yin L; Zhao C; Han J; Li Z; Zhen Y; Xiao R; Xu Z; Sun Y
Ther Clin Risk Manag; 2017; 13():117-130. PubMed ID: 28223815
[TBL] [Abstract][Full Text] [Related]
4. Oncolytic virus oHSV2 combined with PD-1/PD-L1 inhibitors exert antitumor activity by mediating CD4 + T and CD8 + T cell infiltration in the lymphoma tumor microenvironment.
Zhang J; Guo Y; Fang H; Guo X; Zhao L
Autoimmunity; 2023 Dec; 56(1):2259126. PubMed ID: 37736847
[TBL] [Abstract][Full Text] [Related]
5. NK cell tumor therapy modulated by UV-inactivated oncolytic herpes simplex virus type 2 and checkpoint inhibitors.
Wang Y; Jin J; Li Y; Zhou Q; Yao R; Wu Z; Hu H; Fang Z; Dong S; Cai Q; Hu S; Liu B
Transl Res; 2022 Feb; 240():64-86. PubMed ID: 34757194
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of colorectal cancer liver metastasis in BALB/c mice following intratumoral injection of oncolytic herpes simplex virus type 2 for the induction of specific antitumor immunity.
Zhang W; Wang F; Hu X; Liang J; Liu B; Guan Q; Liu S
Oncol Lett; 2019 Jan; 17(1):815-822. PubMed ID: 30655834
[TBL] [Abstract][Full Text] [Related]
7. A novel oncolytic herpes simplex virus type 2 has potent anti-tumor activity.
Zhao Q; Zhang W; Ning Z; Zhuang X; Lu H; Liang J; Li J; Zhang Y; Dong Y; Zhang Y; Zhang S; Liu S; Liu B
PLoS One; 2014; 9(3):e93103. PubMed ID: 24671154
[TBL] [Abstract][Full Text] [Related]
8. Bispecific Antibody Expressed by an Oncolytic Herpes Simplex Virus Type 2 Can Transform Heterologous T Cells Into Uniform Tumor Killer Cells.
Jin J; Wang R; Yang J; Hu H; Wang D; Cai L; Fang Z; Dong S; Hu S; Wang Y; Liu B
Hum Gene Ther; 2022 Jun; 33(11-12):649-663. PubMed ID: 35272497
[TBL] [Abstract][Full Text] [Related]
9. Treatment of colon cancer with oncolytic herpes simplex virus in preclinical models.
Yang H; Peng T; Li J; Wang Y; Zhang W; Zhang P; Peng S; Du T; Li Y; Yan Q; Liu B
Gene Ther; 2016 May; 23(5):450-9. PubMed ID: 26871935
[TBL] [Abstract][Full Text] [Related]
10. Enhanced Therapeutic Efficacy of a Novel Oncolytic Herpes Simplex Virus Type 2 Encoding an Antibody Against Programmed Cell Death 1.
Zhu Y; Hu X; Feng L; Yang Z; Zhou L; Duan X; Cheng S; Zhang W; Liu B; Zhang K
Mol Ther Oncolytics; 2019 Dec; 15():201-213. PubMed ID: 31788554
[TBL] [Abstract][Full Text] [Related]
11. The construction of a new oncolytic herpes simplex virus expressing murine interleukin-15 with gene-editing technology.
Cai L; Hu H; Duan H; Li Y; Zou Z; Luo K; Zhang Z; Yang J; Jin J; Chen Y; Ke Z; Fang Z; Liu Q; Hong X; Hu S; Liu B
J Med Virol; 2020 Dec; 92(12):3617-3627. PubMed ID: 31994741
[TBL] [Abstract][Full Text] [Related]
12. Oncolytic Orf virus licenses NK cells via cDC1 to activate innate and adaptive antitumor mechanisms and extends survival in a murine model of late-stage ovarian cancer.
van Vloten JP; Matuszewska K; Minow MAA; Minott JA; Santry LA; Pereira M; Stegelmeier AA; McAusland TM; Klafuric EM; Karimi K; Colasanti J; McFadden DG; Petrik JJ; Bridle BW; Wootton SK
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35296558
[TBL] [Abstract][Full Text] [Related]
13. Colonization of xenograft tumors by oncolytic vaccinia virus (VACV) results in enhanced tumor killing due to the involvement of myeloid cells.
Kilinc MO; Ehrig K; Pessian M; Minev BR; Szalay AA
J Transl Med; 2016 Dec; 14(1):340. PubMed ID: 27993141
[TBL] [Abstract][Full Text] [Related]
14. [Replication and expression of oncolytic herpes simplex virus type Ⅱ in tumors].
Cai Q; Zhang S; Liu H; Liu B
Sheng Wu Gong Cheng Xue Bao; 2024 Feb; 40(2):585-595. PubMed ID: 38369843
[TBL] [Abstract][Full Text] [Related]
15. Oncolytic Herpes Simplex Virus Encoding IL12 Controls Triple-Negative Breast Cancer Growth and Metastasis.
Ghouse SM; Nguyen HM; Bommareddy PK; Guz-Montgomery K; Saha D
Front Oncol; 2020; 10():384. PubMed ID: 32266155
[TBL] [Abstract][Full Text] [Related]
16. The addition of recombinant vaccinia HER2/neu to oncolytic vaccinia-GMCSF given into the tumor microenvironment overcomes MDSC-mediated immune escape and systemic anergy.
de Vries CR; Monken CE; Lattime EC
Cancer Gene Ther; 2015 Apr; 22(3):154-62. PubMed ID: 25633483
[TBL] [Abstract][Full Text] [Related]
17. Myelolytic Treatments Enhance Oncolytic Herpes Virotherapy in Models of Ewing Sarcoma by Modulating the Immune Microenvironment.
Denton NL; Chen CY; Hutzen B; Currier MA; Scott T; Nartker B; Leddon JL; Wang PY; Srinivas R; Cassady KA; Goins WF; Cripe TP
Mol Ther Oncolytics; 2018 Dec; 11():62-74. PubMed ID: 30505937
[TBL] [Abstract][Full Text] [Related]
18. Modulation of chemokines in the tumor microenvironment enhances oncolytic virotherapy for colorectal cancer.
Francis L; Guo ZS; Liu Z; Ravindranathan R; Urban JA; Sathaiah M; Magge D; Kalinski P; Bartlett DL
Oncotarget; 2016 Apr; 7(16):22174-85. PubMed ID: 26956047
[TBL] [Abstract][Full Text] [Related]
19. Oncolytic herpes virus induces effective anti-cancer immunity against murine colon cancer.
Shirota T; Kasuya H; Kodera Y; Nishikawa Y; Shikano T; Sahin TT; Gewen T; Yamamura K; Fukuda S; Kanzaki A; Yamada S; Fujii T; Sugimoto H; Nomoto S; Takeda S; Nakao A
Hepatogastroenterology; 2011; 58(110-111):1482-9. PubMed ID: 21940320
[TBL] [Abstract][Full Text] [Related]
20. Oncolytic virotherapy enhances the efficacy of a cancer vaccine by modulating the tumor microenvironment.
Koske I; Rössler A; Pipperger L; Petersson M; Barnstorf I; Kimpel J; Tripp CH; Stoitzner P; Bánki Z; von Laer D
Int J Cancer; 2019 Oct; 145(7):1958-1969. PubMed ID: 30972741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
